Tvardi Therapeutics (NASDAQ:TVRD) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other equities analysts have also weighed in on TVRD. Raymond James Financial lowered Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. BTIG Research lowered their price target on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a report on Monday, October 13th. Barclays set a $5.00 price objective on shares of Tvardi Therapeutics and gave the stock an “equal weight” rating in a research note on Monday, October 13th. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 8th. Finally, Piper Sandler cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tvardi Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $55.50.

Tvardi Therapeutics Stock Performance

Shares of TVRD stock opened at $4.22 on Friday. The firm’s 50 day moving average price is $7.54 and its two-hundred day moving average price is $20.99. The stock has a market cap of $39.59 million, a PE ratio of -0.44 and a beta of 0.11. Tvardi Therapeutics has a 52-week low of $3.74 and a 52-week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.24. Tvardi Therapeutics had a negative net margin of 585.37% and a negative return on equity of 282.16%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Slate Path Capital LP bought a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $16,427,000. Vanguard Group Inc. grew its holdings in Tvardi Therapeutics by 5.2% in the third quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock worth $16,335,000 after purchasing an additional 20,757 shares during the last quarter. 683 Capital Management LLC acquired a new position in shares of Tvardi Therapeutics during the second quarter worth $4,107,000. Vestal Point Capital LP acquired a new position in shares of Tvardi Therapeutics during the third quarter worth $6,508,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at $2,617,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.